C. Massard

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

Jean‐Charles Soria, C. Massard, Nicolas Magné et al. · European Journal of Cancer · 2009 · 81 citations

Dose-escalation Study, Oncology, Medicine +5

A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)

A. W. Tolcher, A. Patnaik, E Till et al. · Journal of Clinical Oncology · 2008 · 32 citations

Tumor Biology, Growth Hormone, Humanized Mab +15

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

C. Massard, Jean‐Charles Soria, Anastasios Stathis et al. · European Journal of Cancer · 2016 · 30 citations

Medicine, Pathology, Phase Ib Trial +10

Why do residents choose the medical oncology specialty? Implications for future recruitment—results of the 2007 French Association of Residents in Oncology (AERIO) Survey

Yohann Loriot, Laurence Albiges‐Sauvin, Dimitrios Dionysopoulos et al. · Annals of Oncology · 2009 · 29 citations · Full text

Nursing, Oncology, Patient Selection +8

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

C. Massard, Joaquı́n Mateo, Yohann Loriot et al. · Annals of Oncology · 2016 · 27 citations · Full text